[Using two monoclonal antibodies to detect lung carcinoma associated antigen in the sera of patients with lung cancer by BA-ELISA].

In this study two McAbs (LC86aE4 and LC86aC5) were chosen to detect circulating lung carcinoma associated antigen (LAA) in serum samples from 58 patients with lung cancer, 29 patients with nonmalignant thoracic diseases and 30 healthy donors by biotin-avidin (BA)-ELISA. Our data indicate that BA-ELISA was specific, sensitive, reproducible and simple. The rates of positive detection of LAAE4 or LAAC5 alone were found to be higher (44.8% and 48.3% respectively) in patients with lung cancer than in those with nonmalignant thoracic diseases (13.7%) and in normal donors (6.7%) (P less than 0.01). Furthermore, the combined detection of LAAE4 and LAAC5 resulted in a higher positive rate (62.3%) in lung cancer patients. The clinical application of these McAbs and the assay in the diagnosis of lung cancer is discussed.